Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

Journal:

Journal of Clinical Oncology

Published:

2026-05-02

DOI:

10.1200/jco-25-01525

Affiliations:

19

Authors:

26

Go to article

Institutions	Authors	Share
AbbVie, United States of America (USA)	10.000000 10.000000	0.38
Kyoto University, Japan	1.000000	0.04
Community Health Network, United States of America (USA)	1.000000	0.04
Hadassah Medical Center, HUJI, Israel	1.000000	0.04
Carolina BioOncology Institute (CBI), United States of America (USA)	1.000000	0.04
Yale University, United States of America (USA)	1.000000	0.04
Duke University Health System, United States of America (USA)	1.000000	0.04
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.04
National Cancer Center Hospital East, Japan	1.000000	0.04
START Midwest, United States of America (USA)	1.000000	0.04
Institute of Cancer Research (ICO), France	1.000000	0.04
Rambam Health Care Campus (RambamHCC), IIT, Israel	1.000000	0.04
Centre Georges-François Leclerc (CGFL), France	1.000000	0.04
National Cancer Center Hospital, Japan	1.000000	0.04
NEXT Oncology, United States of America (USA)	1.000000	0.04
Tel Aviv University (TAU), Israel	0.500000	0.02
Chaim Sheba Medical Center at Tel HaShomer, Israel	0.500000	0.02
University of Puerto Rico (UPR), United States of America (USA)	0.500000	0.02
Pan American Center for Oncology Trials (PanOncology), United States of America (USA)	0.500000	0.02

Interested in Oncology and Carcinogenesis?